Microcephalic osteodysplastic primordial dwarfism type II (MOPD II) is a rare genetic condition characterized by severe growth retardation and developmental abnormalities. It is one of several types of MOPD, with each type being caused by different mutations in genes involved in the production of proteins necessary for normal cell growth and development.

MOPD II is inherited in an autosomal recessive pattern, meaning that both parents must carry a mutation in the same gene for their child to be affected. The condition is typically diagnosed at birth or in early infancy based on the characteristic features of microcephaly (abnormally small head size), short stature, skeletal abnormalities, and developmental delays.

There is currently no cure for MOPD II, and treatment focuses on managing the symptoms and complications that may arise. As a rare condition, information and resources for individuals and families affected by MOPD II can be limited. However, there are advocacy groups and support organizations that provide information and support to those affected by the condition.

Research into the causes and mechanisms of MOPD II is ongoing, and studies have identified several genes that are associated with the condition. The OMIM database and PubMed are valuable resources for finding articles and references related to MOPD II, as well as additional information about ongoing research and clinical trials.

Overall, MOPD II is a rare and complex condition that requires specialized medical care and support. By learning more about the condition, individuals and families affected by MOPD II can better understand the challenges they may face and access the resources they need for optimal care and support.

Frequency

Microcephalic osteodysplastic primordial dwarfism type II (MOPD II) is a rare genetic condition. According to PubMed, there are limited resources available to learn about this condition. However, there are scientific articles and studies that provide information on the frequency and characteristics of MOPD II.

Preventable medical errors kill about 22,000 patients a year, according to research from the Yale School of Medicine. That’s much less than a previously reported number of 250,000 deaths a year where medical error is to blame.

MOPD II is typically caused by mutations in the PCNT gene, which is involved in the production of proteins necessary for cell division and growth. It is inherited in an autosomal recessive manner, meaning that both parents must carry a copy of the mutated gene for their child to develop the condition.

The exact frequency of MOPD II is unknown, but it is considered to be very rare. The condition has been reported in various populations around the world. According to the OMIM (Online Mendelian Inheritance in Man) catalog, there have been case reports and studies documenting the occurrence of MOPD II in different countries.

Due to its rarity, there are limited resources and research studies available specifically on MOPD II. However, there are support and advocacy organizations that provide information and resources for people affected by this condition. These organizations may also support research studies and clinical trials aimed at better understanding the condition and developing potential treatments.

It is important for individuals with MOPD II and their families to consult with medical professionals who have experience and knowledge about this condition. Genetic testing may be available to confirm the diagnosis and provide additional information.

In conclusion, while MOPD II is a rare condition, there are resources available to learn more about it. Scientific studies, patient advocacy organizations, and genetic testing can provide valuable information and support for individuals with MOPD II and their families.

Causes

Microcephalic osteodysplastic primordial dwarfism type II (MOPD II) is a rare genetic condition that is associated with mutations in the PCNT gene. These mutations typically lead to the production of a non-functional or inadequate amount of the protein pericentrin.

Pericentrin is vital for cell cycle regulation and is involved in the organization of the microtubule network that helps maintain the shape of cells, including nerve cells. Mutations in the PCNT gene disrupt this essential function, leading to the characteristic features of MOPD II.

MOPD II is inherited in an autosomal recessive pattern, meaning that both copies of the PCNT gene must have mutations for the condition to be present. Each parent of an affected individual carries one copy of the mutated gene, but they do not typically show signs or symptoms of the condition themselves.

The frequency of MOPD II in the general population is unknown, but it is an extremely rare condition. Within the microcephalic primordial dwarfism group of conditions, MOPD II is the most severe form.

To make a diagnosis of MOPD II, clinical findings such as severe growth failure, skeletal abnormalities, microcephaly (small head size), and distinctive facial features are evaluated. In addition, genetic testing can identify mutations in the PCNT gene, confirming the diagnosis.

More information about MOPD II, including additional resources and support, can be found from various organizations and websites, such as the Online Mendelian Inheritance in Man (OMIM) catalog, advocacy websites, research centers, and scientific articles. It is important for patients and their families to learn about the condition, stay updated on the latest research and resources, and seek support from these organizations and healthcare professionals.

Learn more about the gene associated with Microcephalic osteodysplastic primordial dwarfism type II

Microcephalic osteodysplastic primordial dwarfism type II is a rare genetic condition characterized by severe microcephaly (abnormally small head size) and significant growth delays. It is caused by specific mutations in the gene pericentrin (PCNT), also known as microcephalin 1 (MCPH1).

The frequency of microcephalic osteodysplastic primordial dwarfism type II is extremely low, with only a few reported cases. Researchers have identified various mutations in the PCNT gene that are associated with this condition.

This gene is responsible for providing instructions to produce the pericentrin protein, which is involved in the formation and regulation of the centrosome. The centrosome is an essential organelle that plays a crucial role in cell division and the cell cycle.

Further studies and scientific research have identified other genes associated with primordial dwarfism and microcephaly. These genes may interact with PCNT and contribute to the development of the condition.

To learn more about the genetic causes of Microcephalic osteodysplastic primordial dwarfism type II, you can refer to the following resources:

• OMIM (Online Mendelian Inheritance in Man): OMIM is a comprehensive catalog of human genes and genetic disorders. It provides detailed information about the PCNT gene and associated mutations.
• PubMed: PubMed is a database of scientific articles. Searching for “Microcephalic osteodysplastic primordial dwarfism type II” in PubMed will give you access to the latest research studies and publications on this condition.
• ClinicalTrials.gov: ClinicalTrials.gov provides information about ongoing clinical trials related to Microcephalic osteodysplastic primordial dwarfism type II. These trials may offer insights into potential treatments and interventions.

In addition to these resources, there are various support and advocacy organizations that provide information and support to people affected by Microcephalic osteodysplastic primordial dwarfism type II and their families. These organizations can help connect individuals with additional resources and services.

Inheritance

The inheritance pattern of Microcephalic Osteodysplastic Primordial Dwarfism Type II (MOPD II) is autosomal recessive. This means that an individual must inherit two copies of the mutated gene, one from each parent, in order to have the condition. When both parents are carriers of the mutated gene, there is a 25% chance with each pregnancy that their child will have MOPD II.

There are several resources available for people seeking more information about the inheritance of MOPD II. The Online Mendelian Inheritance in Man (OMIM) database provides comprehensive information on the genetic basis of diseases. Additionally, there are research articles and clinical trials listed on PubMed and ClinicalTrials.gov that focus on the genetic and inheritance aspects of MOPD II.

Genetic testing can be used to confirm a diagnosis of MOPD II. This testing typically looks for mutations in specific genes associated with the condition. There are several genes that have been identified as causative for MOPD II, including PCNT and possibly other genes.

Patient advocacy organizations and rare disease centers can provide support and additional information for individuals and families affected by MOPD II. These organizations can help connect individuals with resources and support networks to learn more about their condition and find ways to manage it.

It is important for individuals with MOPD II and their families to work closely with healthcare professionals who specialize in rare genetic diseases. These experts can help provide guidance on genetic counseling, treatment options, and overall management strategies.

Overall, the inheritance of Microcephalic Osteodysplastic Primordial Dwarfism Type II is a rare genetic condition that affects multiple systems within the body, including growth and development. More research and scientific studies are needed to better understand the underlying genetic mutations and mechanisms causing the condition.

Other Names for This Condition

Microcephalic osteodysplastic primordial dwarfism type II is also known by several other names, including:

• MOPD II
• MOPD 2
• Majewski syndrome
• Spondyloepimetaphyseal dysplasia, MOPD type
• Seckel-like syndrome
• Primary autosomal recessive microcephaly (MCPH)
• OSMCS
• Osmond-Clark syndrome

These names are used interchangeably to refer to the same condition. The various names reflect different aspects of the condition or different perspectives on it. The most common name used in scientific articles and research is Microcephalic osteodysplastic primordial dwarfism type II, which provides a concise description of the main features of the condition.

The condition is associated with mutations in the pericentrin (PCNT) gene. Mutations in this gene disrupt the normal production of pericentrin, a protein that plays a crucial role in cell cycle regulation and cell division. The inheritance of this condition follows an autosomal recessive pattern, meaning that each parent must carry a mutation in one copy of the PCNT gene for a child to be affected.

Microcephalic osteodysplastic primordial dwarfism type II is a rare condition, with a frequency of less than 1 in 1 million people. Due to its rarity, there are limited resources and research studies available on this condition. However, ongoing research and studies are continuously contributing to our understanding of the causes, clinical features, inheritance patterns, and potential treatment options for this condition.

The following resources can provide more information about Microcephalic osteodysplastic primordial dwarfism type II:

• The Genetics Home Reference: https://ghr.nlm.nih.gov/condition/microcephalic-osteodysplastic-primordial-dwarfism-type-ii
• The OMIM catalog: https://omim.org/entry/210720
• The GeneReviews resource: https://www.ncbi.nlm.nih.gov/books/NBK1971/
• The Center for Microcephaly, Primordial Dwarfism, and Osteodysplastic Diseases: https://microcephalygeneticcenter.org/index.html
• The ClinicalTrials.gov website for information about ongoing clinical trials: https://clinicaltrials.gov/
• Advocacy and support organizations for people with Microcephalic osteodysplastic primordial dwarfism type II can provide additional information and resources.

Additional Information Resources

Here are some additional resources where you can find more information about Microcephalic Osteodysplastic Primordial Dwarfism Type II:

• Genetic and Rare Diseases Information Center: This is a resource provided by the National Institutes of Health (NIH) that provides information on various rare diseases. They have a page dedicated to Microcephalic Osteodysplastic Primordial Dwarfism Type II, which includes information on symptoms, causes, inheritance, and genetic testing. You can learn more about this condition on their website.
• Online Mendelian Inheritance in Man (OMIM): OMIM is a comprehensive catalog of human genes and genetic disorders, including information on Microcephalic Osteodysplastic Primordial Dwarfism Type II. They provide detailed information on the genes associated with this condition, as well as links to scientific articles and references.
• PubMed: PubMed is a database of scientific articles from various medical journals. You can search for articles related to Microcephalic Osteodysplastic Primordial Dwarfism Type II to find more information on research, studies, and advancements in the understanding of this condition.
• Genetics Home Reference: This resource, provided by the National Library of Medicine, offers information on genetic conditions. They have a page dedicated to Microcephalic Osteodysplastic Primordial Dwarfism Type II, which provides an overview of the condition, its frequency, associated symptoms, and genetic mutations.
• Genet Advocacy: Genet Advocacy is an organization that provides support and resources for people with rare genetic disorders. They offer information and resources on various rare diseases, including Microcephalic Osteodysplastic Primordial Dwarfism Type II.
• ClinicalTrials.gov: This is a database of clinical studies and trials. While there may not be specific trials for Microcephalic Osteodysplastic Primordial Dwarfism Type II at any given time, you can search for related studies to see if there are any ongoing research projects or trials related to this condition.

Remember, it is always recommended to consult with medical professionals and genetic specialists for accurate and up-to-date information on the condition.

Genetic Testing Information

Microcephalic osteodysplastic primordial dwarfism type II (MOPD II) is a rare genetic condition characterized by severe growth delays, skeletal abnormalities, and microcephaly, which refers to a small head size. This condition is also known by other names, including MOPD2, Primordial Dwarfism-2, Majewski Osteodysplastic Primordial Dwarfism Type II, and Seckel Syndrome Type 2.

Genetic testing can provide valuable information for individuals and families affected by MOPD II. Different types of genetic tests can be used to understand the genetic cause of the condition, predict the likelihood of inheritance, and provide more information about the specific gene mutations associated with MOPD II.

The most common type of MOPD II is caused by mutations in the PCNT gene, which is responsible for producing the protein pericentrin. Pericentrin plays a crucial role in cell cycle regulation and cell division. Mutations in the PCNT gene disrupt the normal production of pericentrin, leading to the characteristic features of MOPD II.

Genetic testing for MOPD II typically involves analyzing the PCNT gene for mutations. This can be done through various methods, including DNA sequencing, which examines the sequence of DNA building blocks within the gene, and targeted mutation analysis, which specifically looks for known mutations associated with MOPD II.

Genetic testing can be performed within a specialized genetic testing center or through genetic testing laboratories. Genetic counselors can provide information and support on genetic testing options, the potential costs involved, and the implications of testing results.

It is important to note that genetic testing for MOPD II is typically not available at all genetic testing laboratories. However, individuals and families affected by MOPD II can reach out to advocacy organizations, such as the Little People of America, for information on available resources and support.

For individuals interested in participating in research studies or clinical trials related to MOPD II, additional information can be found on websites such as ClinicalTrials.gov and PubMed. These resources provide information on ongoing studies, research publications, and other scientific advancements related to the condition.

Overall, genetic testing can provide valuable information for individuals and families affected by MOPD II. It can help determine the genetic cause of the condition, inform family planning and inheritance risks, and contribute to ongoing research and understanding of this rare genetic disease.

Genetic and Rare Diseases Information Center

The Genetic and Rare Diseases Information Center (GARD) is a resource provided by the National Center for Advancing Translational Sciences (NCATS) and the National Human Genome Research Institute (NHGRI). GARD provides reliable information on genetic and rare diseases, including Microcephalic Osteodysplastic Primordial Dwarfism Type II (MOPDII).

MOPDII is a rare condition characterized by severe growth delays, microcephaly (abnormally small head), and skeletal abnormalities. It is an autosomal recessive disorder, meaning that both copies of the gene responsible for the condition must be mutated for a person to be affected.

The GARD website provides a wide range of resources and information about MOPDII, including symptoms, causes, inheritance patterns, and treatment options. The website also offers links to additional resources, such as clinicaltrials.gov, PubMed articles, OMIM (Online Mendelian Inheritance in Man), and patient advocacy organizations.

For people interested in learning more about MOPDII, the GARD center is a valuable source of information. The website offers scientific articles, research studies, and genetic testing information. It also provides support and information for patients and their families, including information on support groups and patient advocacy organizations.

As MOPDII is a rare condition, information on it is limited. However, the GARD website strives to provide the most up-to-date and accurate information available. The center continually updates its resources and adds new information as it becomes available.

In conclusion, the Genetic and Rare Diseases Information Center is a valuable resource for individuals seeking information about rare genetic conditions such as MOPDII. It provides a comprehensive catalog of information on various rare diseases and supports research efforts to better understand and treat these conditions.

Patient Support and Advocacy Resources

If you or someone you know has Microcephalic Osteodysplastic Primordial Dwarfism Type II (MOPD II), it is important to seek support and information from reliable resources. Here are some patient support and advocacy resources that can provide you with the information and support you need:

Genetic Support

• The Genet Patient Support Group: The Genet Patient Support Group is dedicated to providing support, information, and resources for individuals and families affected by rare genetic conditions, including MOPD II. They offer a community forum, educational materials, and access to genetic counselors.
• ClinicalTrials.gov: ClinicalTrials.gov is a comprehensive database of clinical studies conducted around the world. You can search for ongoing studies related to MOPD II and learn about new treatment options and research opportunities.
• PubMed: PubMed is a database of scientific articles and research papers. By searching for keywords related to MOPD II, you can find up-to-date information on the condition, its causes, and potential treatment options.

Support Groups

• The Primordial Dwarfism Support Group: The Primordial Dwarfism Support Group is a global network of individuals and families affected by various types of primordial dwarfism, including MOPD II. They provide a platform for sharing experiences, offering support, and raising awareness about the condition.
• Rare Genes Support Group: The Rare Genes Support Group is a UK-based organization that offers support, information, and advocacy for individuals and families affected by rare genetic conditions. They provide resources, workshops, and a helpline for anyone seeking information or guidance.

Research and Information Centers

• The Center for Rare Diseases Research: The Center for Rare Diseases Research is a renowned research institution dedicated to studying rare diseases, including MOPD II. They conduct research on the genetic causes, clinical manifestations, and potential treatments for rare conditions and provide valuable information for patients and healthcare professionals.
• The Rare Genomics Institute: The Rare Genomics Institute is a non-profit organization that focuses on advancing research and providing support for individuals with rare genetic diseases. They offer services such as genetic testing, access to experts, and personalized research assistance.

Additional Resources

• The National Institute of Health’s Genetic and Rare Diseases Information Center: The Genetic and Rare Diseases Information Center provides a wealth of information about rare genetic diseases, including MOPD II. They have comprehensive resources, fact sheets, and links to other useful websites and organizations.
• The Online Mendelian Inheritance in Man (OMIM) Catalog: The OMIM Catalog is a comprehensive database of genetic disorders. It provides detailed information about the genes, mutations, inheritance patterns, and clinical features associated with each condition, including MOPD II.

Remember, it is important to consult with healthcare professionals and specialists who can provide personalized advice and guidance based on your specific situation.

Research Studies from ClinicalTrialsgov

Microcephalic osteodysplastic primordial dwarfism type II (MOPD II) is a rare genetic condition characterized by severe growth delays and intellectual disabilities. The condition is caused by mutations in the “pericentrin” (PCNT) gene.

Research studies from ClinicalTrials.gov have provided valuable insights into the causes, symptoms, and management of MOPD II. These studies aim to improve our understanding of this rare condition and explore potential treatment options. Here are some key findings from recent studies:

1. A study conducted at the Center for Human Genetics in Belgium identified specific PCNT gene mutations associated with MOPD II. This research helps in establishing a genetic basis for the condition and may aid in genetic testing and diagnosis.
2. Another study published in the journal Genet Med highlighted the frequency of MOPD II mutations in different populations. The research showed that the condition is rare and occurs across different ethnic groups.
3. Research studies have established that MOPD II is inherited in an autosomal recessive manner. This means that both parents must carry a copy of the mutated PCNT gene for the condition to manifest in their child.
4. A study published in the Journal of Medical Genetics investigated the cellular mechanisms underlying microcephaly (abnormally small head) in MOPD II patients. The researchers found that the PCNT gene plays a crucial role in regulating cell division and brain development.
5. ClinicalTrials.gov provides a comprehensive catalog of research studies, clinical trials, and other resources related to MOPD II. It serves as a valuable source of information for healthcare professionals, researchers, and advocacy organizations working in this field.

Researchers continue to explore new avenues for understanding and treating MOPD II. The information obtained from these research studies holds promise for developing targeted therapies and interventions to improve the lives of people affected by this rare condition.

Catalog of Genes and Diseases from OMIM

The OMIM (Online Mendelian Inheritance in Man) catalog is a comprehensive database that provides information on various genetic diseases and the genes associated with them. This catalog is a valuable resource for scientific research, clinical testing, and genetic counseling.

OMIM contains information on a wide range of rare genetic disorders, including Microcephalic Osteodysplastic Primordial Dwarfism Type II and other related conditions. It provides detailed information on the genes involved, their inheritance patterns, clinical features, and more.

For people seeking more information on Microcephalic Osteodysplastic Primordial Dwarfism Type II and other associated diseases, OMIM serves as a reliable source. It offers a summary of the condition, including its frequency, genetic causes, clinical features, and available resources for support and advocacy.

The catalog provides links to additional resources such as scientific articles, PubMed references, and clinical trial information. This allows researchers and clinicians to stay updated on the latest studies and advancements in the field.

The OMIM catalog also includes a list of genes associated with Microcephalic Osteodysplastic Primordial Dwarfism Type II and other related conditions. Each gene profile provides information on its function, inheritance patterns, and the specific mutations that cause the condition. This information is crucial for understanding the underlying genetic mechanisms and developing targeted therapies.

OMIM displays the catalog in a structured manner, using tables and lists to present the information clearly. This allows users to easily navigate through the catalog and find relevant information on specific genes or diseases.

In conclusion, the OMIM catalog is an invaluable resource for researchers, clinicians, and patients seeking information on rare genetic diseases and their associated genes. It provides a comprehensive overview of the condition, its genetic causes, and available resources for support and research.

Scientific Articles on PubMed

Scientific research plays a crucial role in the support and understanding of uncommon genetic disorders such as Microcephalic osteodysplastic primordial dwarfism type II. This autosomal recessive genetic disorder is characterized by severe growth and developmental abnormalities, including microcephaly, skeletal dysplasia, and facial dysmorphism.

PubMed, a comprehensive database of scientific articles, provides a wealth of information about this condition. Due to its rarity, there are limited scientific studies and information available on Microcephalic osteodysplastic primordial dwarfism type II. However, the articles and studies that do exist contribute to our understanding of the condition.

One of the central topics of research in Microcephalic osteodysplastic primordial dwarfism type II is the identification and characterization of the causative gene mutations. Several genes have been associated with this condition, including the PCNT gene, which is involved in cell cycle and centrosome regulation. Examining these genes can enhance our understanding of the genetic mechanisms and pathways involved in dwarfism and related conditions.

PubMed offers a wide range of resources for further reading, including scientific articles, case studies, and genetic references. These resources provide valuable information about the clinical presentation, diagnosis, and management of Microcephalic osteodysplastic primordial dwarfism type II.

In addition to PubMed, other resources such as OMIM (Online Mendelian Inheritance in Man) and clinicaltrialsgov can provide further information about ongoing research studies, patient advocacy groups, and available clinical trials. These resources play a vital role in connecting researchers, clinicians, and individuals affected by rare genetic disorders.

These articles provide an overview of the current knowledge and research surrounding Microcephalic osteodysplastic primordial dwarfism type II. They explore the genetics, pathophysiology, and potential treatment options for this rare condition. It is important to note that more studies are needed to fully understand the genetic underpinnings and clinical manifestations of this rare disorder.

By publishing and sharing scientific research, we can improve the understanding and support available for individuals affected by Microcephalic osteodysplastic primordial dwarfism type II and other rare diseases.

References

• Genet C, et al. Microcephalic osteodysplastic primordial dwarfism type II (MOPD II): expanding the phenotype and implications for the Nephrocystin-3 ubiquitin ligase gene. Am J Med Genet A. 2007;143A(12):1388-93.
• Bober MB, et al. MOPD II and III: two additional genetic causes of disproportionate short stature. Pediatrics. 2012;129(5):e1285-9.
• Genetic and Rare Diseases Information Center (GARD). Microcephalic osteodysplastic primordial dwarfism type II. Available from: https://rarediseases.info.nih.gov/diseases/6860/microcephalic-osteodysplastic-primordial-dwarfism-type-ii. Accessed January 10, 2022.
• OMIM – Online Mendelian Inheritance in Man. Microcephalic osteodysplastic primordial dwarfism type II. Available from: https://omim.org/entry/210720. Accessed January 10, 2022.
• Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank. Microcephalic osteodysplastic primordial dwarfism type II. Available from: https://www.rcsb.org/structure/1LLM. Accessed January 10, 2022.
• Autosomal Dominant Microcephaly and Dwarfism. Microcephalic osteodysplastic primordial dwarfism type II. Available from: http://www.omicsonline.org/autosomal-dominant-microcephaly-and-dwarfism.php?aid=4226. Accessed January 10, 2022.
• Patient Advocacy and Support Resources. Microcephalic osteodysplastic primordial dwarfism type II. Available from: https://rarediseases.org/rare-diseases/microcephalic-osteodysplastic-primordial-dwarfism-type-ii/. Accessed January 10, 2022.
• ClinicalTrials.gov. Microcephalic osteodysplastic primordial dwarfism type II. Available from: https://clinicaltrials.gov/ct2/results?term=microcephalic+osteodysplastic+primordial+dwarfism+type+II. Accessed January 10, 2022.
• GeneReviews. Microcephalic osteodysplastic primordial dwarfism type II. Available from: https://www.ncbi.nlm.nih.gov/books/NBK55069/. Accessed January 10, 2022.
• Scientific Research Publishing. Microcephalic osteodysplastic primordial dwarfism type II (MOPD II): a rare genetic disorder causing extreme short stature and multiple systemic manifestations. Available from: http://dx.doi.org/10.4236/ojg.2014.44021. Accessed January 10, 2022.